Byetta Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
Links shared publicly online about this topic.
- 1,631total visits
Byetta Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
View full resource at drugs.com
Tags: Diabetes, Diabetes Type 2 Medication, Diabetes Medication, Type 2 Diabetes, Byetta
Most Recently Shared on November 3, 2009 at 12:18 am By:
Byetta Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes - http://bit.ly/q10EZ
Expanded approval for Byetta; but also renal warning
theheart.org — “The FDA has issued a warning about exenatide the same day the agency approved its first-line use along with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.” View full resource at theheart.org
Most Recently Shared on November 3, 2009 at 6:41 pm By:
heartwire: FDA expands exenatide use; warns of renal-failure risk http://bit.ly/O9Drq
Byetta gains expanded indication for first-line treatment for type 2 diabetes - MPR
empr.com — “The FDA has approved Byetta (exenatide injection, from Amylin and Lilly), a GLP-1 receptor agonist, for use as monotherapy along with diet and exercise to improve glycemic control in adults with type 2 diabetes.” View full resource at empr.com
Most Recently Shared on November 2, 2009 at 2:25 pm By:
MPR News: Byetta gains expanded indication for first-line treatment for type 2 diabetes: The FDA has approved Byetta... http://bit.ly/4kc5TM
Eli Lilly and Company - BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
newsroom.lilly.com — “Eli Lilly and Company - BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes” View full resource at newsroom.lilly.com
Most Recently Shared on November 1, 2009 at 3:10 pm By:
eyeonfda Pharma and Health Lawyer
BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes - http://bit.ly/3SxCxX
BYETTA Approved For Expanded Use As First-Line Treatment For Type 2 Diabetes
medicalnewstoday.com — “Amylin pharmaceuticals, inc., (nasdaq: amln) and eli lilly and company (nyse: lly) announced that the u.s. food and drug administration (fda) has approved an expanded indication for byetta® (” View full resource at medicalnewstoday.com
Most Recently Shared on October 31, 2009 at 12:12 pm By:
MNT Clinical Trials Health News
BYETTA Approved For Expanded Use As First-Line Treatment For Type 2 Diabetes: Amylin Pharmaceuticals, Inc., (Na.. http://bit.ly/FO6jd
Advertisement
